Lv4
520 积分 2021-08-31 加入
Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03
2天前
求助中
p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2+ breast cancer that limits trastuzumab deruxtecan efficacy
1个月前
已完结
Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer
1个月前
已完结
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: MAINTAIN Trial
1个月前
已完结
Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer and Emerging Therapeutic Opportunities
1个月前
已完结
Ribociclib plus Endocrine Therapy in Early Breast Cancer
3个月前
已完结
PTEN promoter methylation and expression in endometrial cancer tissues
3个月前
已完结
Targeting brain metastases in breast cancer
4个月前
已完结
Efficacy of trastuzumab deruxtecan in an advanced gastric cancer patient with brain metastasis
4个月前
已完结
皖公网安备34019202002308
